OptiNose (OPTN)
(Delayed Data from NSDQ)
$0.76 USD
-0.03 (-4.27%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.75 -0.01 (-1.52%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
OptiNose, Inc. [OPTN]
Reports for Purchase
Showing records 1 - 6 ( 6 total )
Company: OptiNose, Inc.
Industry: Medical - Drugs
Targeting XHANCE Growth in CRS-Only Approval in Non-Polyp Patients; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: OptiNose, Inc.
Industry: Medical - Drugs
Positive Initial XHANCE Launch Now Utilizing Expanded CRS Label; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: OptiNose, Inc.
Industry: Medical - Drugs
Model Updates With Positive XHANCE Launch Guidance; Reit. Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: OptiNose, Inc.
Industry: Medical - Drugs
XHANCE Label Extension Defines First FDA Approval for CRSsNP Patients; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: OptiNose, Inc.
Industry: Medical - Drugs
Near-Term XHANCE PDUFA for First Approval in Chronic Sinusitis Without Nasal Polyps; Initiating With Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: OptiNose, Inc.
Industry: Medical - Drugs
|